BMG PHARMA S.r.l announces the signature of a Distribution Agreement for its Cancer Supportive Care line including its iron in liposomal technology based product with Sayre Therapeutics for India and other Asian area countries.

July 30th 2015

BMG Pharma S.r.l. is pleased to announce the signature of a Distribution Agreement with Sayre Therapeutics Ltd, Bangalore, India, for its cancer supportive products under the brand name GelX® and for its liposomal iron based food supplement   IronOne.

Thanks to its innovative formulas, the GelX® range alleviates pain in oncological patients, offering different solutions for chemotherapy & radiation induced oral mucositis, xerostomia, dry mouth and radiation dermatitis.

IronOne is a new iron concept, available in softgel capsules, utilizing a unique coating technology in liposomes to create a product, which allows the molecule to pass through the stomach, avoiding gastrointestinal irritation. This means that the iron is absorbed directly through the lining of the gastrointestinal tract, proving it extremely effective,

”We are proud to cooperate with Sayre who we have signed up with as our preferred and exclusive partner in achieving registration & distribution of the products in their territory” – said Marco Mastrodonato, CEO of BMG Pharma S.r.l. – “We are pleased to offer our products to allow patients to receive the best care possible by using innovative formulations to provide fast pain relief for oncologic and anemic patients “This partnership is a major milestone for BMG as it allows our company to enter the Indian and south Asian market and we are sure that Sayre will implement strong strategies in order to support the distribution of our products in all these markets”.

A Sayre spokesperson said “Our collaboration with BMG Pharma S.r.l. provides a tremendous boost to our efforts to bring cutting-edge cancer supportive care products to the Indian subcontinent. Sayre is committed to making available life-saving medicines in South Asia, to benefit the patient community and improve their quality of life.” “We are thrilled to partner with BMG Pharma S.r.l. to fulfill a high unmet need segment and explore newer therapies in cancer in the future.

About SAYRE:
M/S Sayre Therapeutics Private Ltd. is South Asia’s only integrated platform for disease management backed by a unique distribution and commercialization model for novel and/or differentiated drugs, companion diagnostics and drug-delivery devices in the super-specialty areas of Oncology and Immunology. Companies with novel Oncology and Immunology assets can work with us in South Asia, as we focus on alleviating life-threatening diseases with high unmet need.

For press releases and other company information, visit:
www.sayretherapeutics.com
Contact : Ms. Chandana Balasubramanian
Chandana.balasubramanian@sayretherapeutics.com

About BMG
BMG is a specialty pharmaceutical company with head office in Milan, Italy, leveraging its proprietary technology to develop products that address unmet needs of patients. The company is currently focused on cancer supportive care, dermatology gynecology, ENT and oral health. BMG Pharma. is dedicated to helping patients, pharmacists and physicians by providing valuable and innovative products to the market.

The Company’s key features are:

  • Full involvement in business and partnering
  • Presence in different therapeutic areas
  • Specific regulatory strategies for each product as Prescription and OTC Medical Devices in EC and US to allow rapid market introduction. BMG focuses on bringing products to market quickly with supportive clinical data.
  • IP protection for most of the products and technologies

For press releases and other company information, visit:
www.bmgpharma.com
and contact : Mrs. Loredana Galli
loredana.galli@bmgpharma.com

BMG Pharma S.r.l.